TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma

This study is testing whether adding an immunotherapy drug to a combination of chemotherapy and radiation can improve survival for people with locally advanced esophageal squamous cell carcinoma (cancer of the food tube) who cannot or choose not to have surgery. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with stage II–IV esophageal squamous cell carcinoma (with spread limited to nearby lymph nodes at most) - Surgery is not possible or you have declined it - You are in good functional health (ECOG 0–1) - Your expected survival is more than 3 months **You may NOT be eligible if...** - You have had an esophageal or tracheal stent placed - Your tumor has invaded major blood vessels or the airway and poses a high risk of bleeding or perforation - You have had another cancer in the past 3 years - You have previously received immune checkpoint therapy (anti-PD-1/PD-L1) or similar drugs - You are currently in another clinical trial Talk to your doctor to see if this trial is right for you.